Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
Gastroenterol Hepatol (N Y)
.
2023 Dec;19(12 Suppl 9):9-10.
PMID:
38445187
PMCID:
PMC10910380
No abstract available